Australiahea

US citizens who were on the Hondius cruise ship hit by a hantavirus outbreak are now being isolated in Nebraska. One person is in a specialized biocontainment unit after testing positive for the rare respiratory disease. Shares of Moderna are rising after the company said it's working on a vaccine. Sam Fazeli of Bloomberg Intelligence has more.

US employers added 115,000 jobs in April, marking the first back-to-back advance in nearly a year, and the unemployment rate remained unchanged at 4.3%. Bloomberg's Michael McKee has our first read on the report.

Dr. Mehmet Oz, administrator of the Centers for Medicare & Medicaid Services, talks about how the White House is making prescription drugs more affordable, fighting fraud in healthcare, and the future of Medicare. He speaks to Bloomberg Television at the Milken Global Conference.

Novo Nordisk said this year's declines won't be as bad as initially expected thanks to the new Wegovy pill, which helped fuel sales in the first quarter. For the year, the worst drop for both profit and sales will be 12%, compared with 13% earlier. Bloomberg's Sanne Wass reports from Copenhagen.

Pfizer Inc. Chief Executive Officer Albert Bourla says President Donald Trump's nominee to lead the Centers for Disease Control and Prevention is a good choice. Bourla says Erica Schwartz is a "very credible scientist." Bourla also talks about earnings, their drug pipeline and doing business in China. He speaks to Bloomberg's David Westin.

Regis Healthcare Limited (ASX: REG) has announced a third-quarter update, projecting a full-year underlying EBITDA of approximately $135 million.

Shaojing Tong, CFO at Chinese biotech firm RemeGen, discusses the company's first quarter results and shares his confidence in growth in the domestic market. The company's stock has outperformed all of its peers in the MSCI China Healthcare Index since the start of the year.

EBOS Group (ASX:EBO) revised its FY26 earnings guidance downward as the company grapples with a material surge in fuel and energy-related expenses.

UnitedHealth is bouncing back after a tough year, using higher premiums to drive stronger results even as enrollment dips. At the same time, its role in a major Medicare drug initiative and rising healthcare costs are shaping the future outlook for the entire insurance industry. Bloomberg health reporter Ike Swetlitz joined Bloomberg Open Interest to break down the results.

Actinogen Medical (ASX:ACW) announced the commencement of the open-label extension phase for its pivotal XanaMIA trial.